GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
TH 302: New Drug May Make Tumors Less Resistant to Treatment
Dr. Jonathan Goldman discusses a drug currently being studied that ...
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
-
HD
Should We Do Broad Sequencing of All Lung Tumors?
How much detail is needed when determining how to treat ...
How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.
-
HD
How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
Xalkori (crizotinib) has had great success treating ALK positive lung ...
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.
-
HD
Why Are Non-Mutated EGFR Genes Called "Wild Type?"
When it comes to EGFR and lung cancer, is a ...
When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called "wild type." February 2014.
-
HD
Teaching the Immune System to Attack Lung Cancer Tumors
Immune therapy, or immunotherapy, is one of the most exciting ...
Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.
-
HD
Advice for Lung Cancer Patients: Know Thy Cancer
What should lung cancer patients know about their disease? Dr. ...
What should lung cancer patients know about their disease? Dr. Jonathan Riess argues that patients should understand what type of lung cancer they have and which, if any, mutations their lung tumors may have. He explains why in this video.
-
HD
Is It Necessary for Early Stage Lung Cancer Patients to Get Molecular Testing for Their Tumors?
If you were diagnosed with early stage lung cancer, should ...
If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal of Stanford University Medical Center discusses the reasons for and against it. February 2014.
-
HD
Treating EGFR Patients After Tarceva Stops Working
Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, ...
Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center talks about the next generation EGFR inhibitors that may soon become...
-
HD
Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive Non-small Cell Lung Cancer?
Dr. Joel Neal of Stanford University Medical Center discusses the ...
Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients and whether or not Tarceva (erlotinib) would prevent disease recurrence. February 2014.
-
HD
An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?
Dr. Heather Wakelee of Stanford University Medical Center talks about ...
Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.
